Neurocrine Biosciences Inc. (NASDAQ:NBIX) reported fourth-quarter adjusted EPS of $1.69, higher than the $1.54 reported a ...
TipRanks on MSN17h
Neurocrine Biosciences’ Earnings Call: Record Sales & Strategic GrowthNeurocrine Biosciences (($NBIX)) has held its Q4 earnings call. Read on for the main highlights of the call. Neurocrine Biosciences’ earnings call ...
Investor's Business Daily on MSN20h
Neurocrine Crumbles On Lackluster Guidance For Its Bread-And-Butter DrugNeurocrine stock took a hit late Thursday after the biotech company issued a light 2025 outlook for its drug, Ingrezza.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback